Ana M. Molina
- Cancer Research top 1%
- Cancer Genomics and Diagnostics 27
- Pulmonary and Respiratory Medicine top 0.5%
- Prostate Cancer Treatment and Research 53
- Renal cell carcinoma treatment 52
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers 22
- Molecular Biology top 5%
- Renal and related cancers 28
-
- Radiopharmaceutical Chemistry and Applications 47
- Medical Imaging Techniques and Applications 13
-
- Bladder and Urothelial Cancer Treatments 12
- Co-authors
- Robert J. MotzerDavid M. NanusScott T. TagawaThomas E. HutsonMartin H. VossM. Dror MichaelsonSujata PatilDarren R. Feldman
- Partner nations
- United StatesUnited KingdomIsrael
In The Last Decade
Ana M. Molina
123 papers receiving 3.5k citations
Hit Papers
Peers
Comparison fields: 5 of 93
- Cancer Research 1.2k
- Pulmonary and Respiratory Medicine 2.5k
- Oncology 1.2k
- Molecular Biology 1.7k
- Radiology, Nuclear Medicine and Imaging 513
Countries citing papers authored by Ana M. Molina
This map shows the geographic impact of Ana M. Molina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana M. Molina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana M. Molina more than expected).
Fields of papers citing papers by Ana M. Molina
This network shows the impact of papers produced by Ana M. Molina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana M. Molina. The network helps show where Ana M. Molina may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ana M. Molina, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2023 | 8 | |
| 3 | 2023 | 3 | |
| 4 | 2023 | 6 | |
| 5 | 2022 | 7 | |
| 6 | 2022 | 4 | |
| 7 | 2022 | 5 | |
| 8 | 2021 | 0 | |
| 9 | 2021 | 3 | |
| 10 | 2020 | 27 | |
| 11 | 2020 | 38 | |
| 12 | Clinical features of neuroendocrine prostate cancerbreakdown → | 2019 | 232 |
| 13 | 2019 | 6 | |
| 14 | 2018 | 48 | |
| 15 | 2017 | 33 | |
| 16 | 2016 | 1 | |
| 17 | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trialbreakdown → | 2015 | 688 |
| 18 | 2014 | 30 | |
| 19 | 2010 | 27 | |
| 20 | 2007 | 1 |
About Ana M. Molina
Ana M. Molina is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 129 papers that have together received 3.5k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (53 papers), Renal cell carcinoma treatment (52 papers), Radiopharmaceutical Chemistry and Applications (47 papers), Renal and related cancers (28 papers), Cancer Genomics and Diagnostics (27 papers), Cancer Immunotherapy and Biomarkers (22 papers), Medical Imaging Techniques and Applications (13 papers) and Bladder and Urothelial Cancer Treatments (12 papers). The work is most often cited by research in Cancer Research (1.2k citations), Pulmonary and Respiratory Medicine (2.5k citations) and Oncology (1.2k citations). Ana M. Molina has collaborated with scholars based in United States, United Kingdom and Israel. Frequent co-authors include Robert J. Motzer, David M. Nanus, Scott T. Tagawa, Thomas E. Hutson, Martin H. Voss, M. Dror Michaelson, Sujata Patil, Darren R. Feldman, James Larkin and Karen Wood. Their work appears in journals such as Nature Genetics, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.